Want to see IN:BLISSGVS full AI Analyst Report?
Top Page
Bliss Gvs Pharma Limited
(BLISSGVS)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹781.00
▲(439.55% Upside)
Action:Reiterated
Date:08/20/26
The score is driven primarily by strong financial performance, led by a low-leverage balance sheet and improving recent profitability/free cash flow. Technicals add support due to a clear uptrend, but overbought signals temper the near-term outlook. Valuation is the key drag given the high P/E and low dividend yield.
Positive Factors
Steady revenue growth
Consistent revenue expansion indicates ongoing demand for the company’s pharmaceutical formulations across its markets. Continued top-line growth can support scale benefits, broader market reach, and reinvestment in products and distribution over the next several quarters.
Negative Factors
Historically volatile profitability
Past swings in margins and earnings indicate that profitability has not been uniformly durable across reporting periods. Such variability makes future earnings power less predictable and may limit confidence in maintaining recent profit improvement over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Consistent revenue expansion indicates ongoing demand for the company’s pharmaceutical formulations across its markets. Continued top-line growth can support scale benefits, broader market reach, and reinvestment in products and distribution over the next several quarters.
Read all positive factors
Bliss Gvs Pharma Limited (BLISSGVS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹73.62B
Dividend Yield0.21%
Average Volume (3M)19.38K
Price to Earnings (P/E)54.8
Beta (1Y)1.18
Revenue Growth20.59%
EPS Growth27.16%
CountryIN
Employees1,033
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.78
Shares Outstanding106,275,220
10 Day Avg. Volume15,752
30 Day Avg. Volume19,383
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.03
Price to Sales (P/S)2.61
P/FCF Ratio29.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bliss Gvs Pharma Limited Business Overview & Revenue Model
Company Description
Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes a...
How the Company Makes Money
Bliss GVS Pharma makes money primarily by selling pharmaceutical formulations (finished dosage medicines) to customers in India and overseas. Its revenue model is centered on (1) domestic formulation sales through marketing and distribution channe...
Bliss Gvs Pharma Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
69
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.05B | 9.27B | 8.10B | 7.66B | 7.47B | 7.38B |
| Gross Profit | 4.63B | 5.02B | 3.96B | 2.49B | 3.50B | 3.47B |
| EBITDA | 2.35B | 2.35B | 1.27B | 1.49B | 1.35B | 762.37M |
| Net Income | 1.36B | 1.29B | 842.99M | 754.54M | 708.59M | 150.40M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 14.92B | 13.01B | 12.14B | 11.57B | 11.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.89B | 1.89B | 1.41B | 1.41B | 684.11M | 1.35B |
| Total Debt | 0.00 | 217.50M | 881.04M | 998.40M | 1.02B | 1.09B |
| Total Liabilities | -12.32B | 2.61B | 2.09B | 2.11B | 2.39B | 2.62B |
| Stockholders Equity | 12.32B | 11.93B | 10.50B | 9.67B | 8.84B | 8.19B |
Cash Flow | ||||||
| Free Cash Flow | 483.04M | 818.87M | 298.48M | 1.24B | -594.86M | 614.77M |
| Operating Cash Flow | 775.52M | 1.39B | 1.06B | 1.52B | 343.13M | 1.35B |
| Investing Cash Flow | -272.20M | -382.80M | -754.41M | -1.33B | -77.51M | -929.75M |
| Financing Cash Flow | -448.06M | -892.11M | -303.45M | -208.93M | -249.38M | -237.30M |
Bliss Gvs Pharma Limited Technical Analysis
Positive
144.75
Price Trends
536.22
Positive
453.06
Positive
322.48
Positive
Market Momentum
51.73
Negative
72.49
Negative
85.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 144.75 is below the 20-day moving average (MA) of 609.16, below the 50-day MA of 536.22, and below the 200-day MA of 322.48, indicating a bullish trend. The MACD of 51.73 indicates Negative momentum. The RSI at 72.49 is Negative, neither overbought nor oversold. The STOCH value of 85.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.
Bliss Gvs Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹46.57B | 38.47 | ― | 0.86% | 11.78% | -34.54% | |
72 Outperform | ₹73.62B | 54.81 | ― | 0.21% | 20.59% | 27.16% | |
64 Neutral | ₹61.57B | 36.96 | ― | 0.47% | 18.56% | 60.06% | |
63 Neutral | ₹68.23B | 43.38 | ― | 0.17% | 34.47% | 20.42% | |
61 Neutral | ₹51.86B | 594.21 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹38.19B | 12.31 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:BLISSGVS
Bliss Gvs Pharma Limited
703.70
551.13
361.23%
IN:INNOVACAP
Innova Captab Limited
1,167.45
309.89
36.14%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
211.30
101.87
93.10%
IN:ORCHPHARMA
Orchid Pharma Limited
1,015.25
309.10
43.77%
IN:RPGLIFE
RPG Life Sciences Limited
2,777.50
402.32
16.94%
IN:UNICHEMLAB
Unichem Laboratories Limited
533.05
34.85
7.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.